WO2006061650A3 - Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature - Google Patents

Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature Download PDF

Info

Publication number
WO2006061650A3
WO2006061650A3 PCT/GB2005/004764 GB2005004764W WO2006061650A3 WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3 GB 2005004764 W GB2005004764 W GB 2005004764W WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
agents
gpvi
vasculature
products
Prior art date
Application number
PCT/GB2005/004764
Other languages
English (en)
Other versions
WO2006061650A2 (fr
Inventor
Goetz Muench
Andreas Bueltmann
Oliver Vimpany Arnold Boucher
Suresh Babubhai Chahwala
Meinrad Gawaz
Martin Ungerer
Original Assignee
Trigen Gmbh
Trigen Ltd
Goetz Muench
Andreas Bueltmann
Oliver Vimpany Arnold Boucher
Suresh Babubhai Chahwala
Meinrad Gawaz
Martin Ungerer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/009,106 external-priority patent/US7531178B2/en
Application filed by Trigen Gmbh, Trigen Ltd, Goetz Muench, Andreas Bueltmann, Oliver Vimpany Arnold Boucher, Suresh Babubhai Chahwala, Meinrad Gawaz, Martin Ungerer filed Critical Trigen Gmbh
Priority to EP05849048A priority Critical patent/EP1824979A2/fr
Priority to US11/792,857 priority patent/US20090130021A1/en
Publication of WO2006061650A2 publication Critical patent/WO2006061650A2/fr
Publication of WO2006061650A3 publication Critical patent/WO2006061650A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des agents interférant avec la liaison de GPVI à divers composants. L'invention concerne également des agents interférant avec l'interaction de GPVI avec la fibronectine et/ou la vironectine ou des séquences de celles-ci. L'invention concerne, en outre, des méthodes de traitement de troubles ou de maladies impliquant une interaction pathologique, dysfonctionnelle ou non pathologique de GPVI avec la fibronectine et/ou la vitronectine. L'invention concerne enfin l'utilisation d'agents dans la prévention ou le traitement de troubles engendrés par l'adhésion et l'agrégation de plaquettes du sang.
PCT/GB2005/004764 2002-06-07 2005-12-12 Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature WO2006061650A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05849048A EP1824979A2 (fr) 2004-12-10 2005-12-12 Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
US11/792,857 US20090130021A1 (en) 2002-06-07 2005-12-12 Methods, products and uses involving platelets and/or the vasculature

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/009,106 US7531178B2 (en) 2002-06-07 2004-12-10 Immunoadhesin comprising a glycoprotein VI domain
US11/009,106 2004-12-10
EP05256993 2005-11-11
EP05256993.6 2005-11-11

Publications (2)

Publication Number Publication Date
WO2006061650A2 WO2006061650A2 (fr) 2006-06-15
WO2006061650A3 true WO2006061650A3 (fr) 2006-08-17

Family

ID=36337522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004764 WO2006061650A2 (fr) 2002-06-07 2005-12-12 Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature

Country Status (2)

Country Link
EP (1) EP1824979A2 (fr)
WO (1) WO2006061650A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091719A1 (fr) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. Thérapie concomitante par anticorps anti-gpvi et son utilisation médicinale novatrice
CA2646807A1 (fr) 2006-03-31 2007-10-18 Mochida Pharmaceutical Co., Ltd. Nouveau marqueur de l'activation plaquettaire et son procede de determination
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
CN102026659A (zh) * 2008-04-22 2011-04-20 Csl百灵有限公司 通过抑制gpvi预防和治疗癌症的方法
US8318923B2 (en) 2009-06-03 2012-11-27 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8889646B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8889645B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
EP2460541B1 (fr) * 2009-07-30 2018-01-17 FUJIFILM Corporation Agent d'imagerie rénale comprenant de la gélatine recombinante
EA201290525A1 (ru) * 2009-12-18 2013-01-30 Санофи Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
EP2336188A1 (fr) * 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2397495A1 (fr) * 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
AR082404A1 (es) 2010-07-28 2012-12-05 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de inmunoglobulinas fc ordenadamente multimerizadas
US10468565B2 (en) 2012-06-11 2019-11-05 Cree, Inc. LED package with multiple element light source and encapsulant having curved and/or planar surfaces
AU2013305885B2 (en) 2012-08-20 2017-12-21 Gliknik Inc. Molecules with antigen binding and polyvalent Fc gamma receptor binding activity
CA3026420A1 (fr) 2016-06-07 2017-12-14 Gliknik Inc. Stradomeres optimises par la cysteine
EP3551227A4 (fr) 2016-12-09 2020-07-29 Gliknik Inc. Méthodes de traitement de troubles inflammatoires avec des composés fc multivalents
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
CN108918564B (zh) * 2018-08-09 2021-02-02 陕西延长石油(集团)有限责任公司研究院 一种适用于泥页岩矿物成分定量的分析方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080968A1 (fr) * 2001-04-09 2002-10-17 Millennium Pharmaceuticals, Inc. Glycoproteine vi et utilisations de cette derniere
WO2003008454A2 (fr) * 2001-07-18 2003-01-30 Merck Patent Gmbh Proteine de fusion, glycoproteine vi
WO2003104282A2 (fr) * 2002-06-07 2003-12-18 Procorde Gmbh Immunoadhesine comprenant un domaine de glycoproteine vi
WO2005007674A2 (fr) * 2003-07-11 2005-01-27 Molecular Innovations Anticorps anti-vitronectine humaine et methodes de fabrication de celui-ci
WO2005054294A2 (fr) * 2003-12-03 2005-06-16 Trigen Gmbh Inhibiteurs d'une glycoproteine vi a base d'un anticorps monoclonal hgp 5c4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080968A1 (fr) * 2001-04-09 2002-10-17 Millennium Pharmaceuticals, Inc. Glycoproteine vi et utilisations de cette derniere
WO2003008454A2 (fr) * 2001-07-18 2003-01-30 Merck Patent Gmbh Proteine de fusion, glycoproteine vi
WO2003104282A2 (fr) * 2002-06-07 2003-12-18 Procorde Gmbh Immunoadhesine comprenant un domaine de glycoproteine vi
WO2005007674A2 (fr) * 2003-07-11 2005-01-27 Molecular Innovations Anticorps anti-vitronectine humaine et methodes de fabrication de celui-ci
WO2005054294A2 (fr) * 2003-12-03 2005-06-16 Trigen Gmbh Inhibiteurs d'une glycoproteine vi a base d'un anticorps monoclonal hgp 5c4

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CIERNIEWSKI C ET AL: "Anti-(Arg-Gly-Asp-Ser) antibody and its interaction with fibronectin, fibrinogen and platelets", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 177, no. 1, October 1988 (1988-10-01), pages 109 - 115, XP002099824, ISSN: 0014-2956 *
GRÜNER S ET AL: "Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 105, no. 4, 15 February 2005 (2005-02-15), pages 1492 - 1499, XP002375721, ISSN: 0006-4971 *
SCHULZ CHRISTIAN ET AL: "Glycoprotein VI mediates platelet adhesion to endothelial cells in vivo", CIRCULATION, vol. 112, no. 17, Suppl. S, October 2005 (2005-10-01), & 78TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 13 -16, 2005, pages U93, XP009067061, ISSN: 0009-7322 *
SMETHURST PETER A ET AL: "Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody.", BLOOD, vol. 103, no. 3, 1 February 2004 (2004-02-01), pages 903 - 911, XP002383117, ISSN: 0006-4971 *
WU YA-PING ET AL: "Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.", BLOOD. 15 AUG 2004, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1034 - 1041, XP002383118, ISSN: 0006-4971 *
YANG C H ET AL: "Inhibition of RPE cell-mediated matrix adhesion and collagen gel contraction by crovidisin, a collagen-binding snake venom protein.", CURRENT EYE RESEARCH. NOV 1997, vol. 16, no. 11, November 1997 (1997-11-01), pages 1119 - 1126, XP009067064, ISSN: 0271-3683 *

Also Published As

Publication number Publication date
EP1824979A2 (fr) 2007-08-29
WO2006061650A2 (fr) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006061650A3 (fr) Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
WO2007117381A3 (fr) Activateurs de glucokinase
WO2008157733A3 (fr) Gel de fibrine pour libération régulée de pdgf et utilisations de celui-ci
EP2319925A3 (fr) Utilisations thérapeutiques d'inhibiteurs du RTP801
EP3050876A3 (fr) Modulateurs de kinase
WO2007005879A3 (fr) Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
WO2009134776A3 (fr) Immunoglobulines à double domaine variable et utilisations
WO2009149185A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
NO20062767L (no) Immunoglobuliner
WO2010006060A3 (fr) Immunoglobulines à double domaine variable de prostaglandine e2 et leurs utilisations
WO2007053189A3 (fr) Compositions et méthodes pour altérer une fonction immunitaire
WO2006099111A3 (fr) Reducteurs d'anevrismes
WO2011028811A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
ATE473636T1 (de) Nahrungsmittel mit probiotischem und isoliertem beta-glukan und verwendungsverfahren dafür
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
WO2009070740A3 (fr) Nouveaux composés et nouvelles compositions et leurs procédés d'utilisation
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
WO2006122046A3 (fr) Therapies pour maladies vasculaires
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2007084684A3 (fr) Utilisations therapeutiques d’inhibiteurs de rtp801
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2006102061A3 (fr) Methode de reduction de la calcification
WO2007068750A3 (fr) Immunoglobulines
WO2007135571A3 (fr) Antigènes de groupes sanguins de types différents pour applications diagnostiques et thérapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005849048

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005849048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11792857

Country of ref document: US